Abstract
Customized chemotherapy is likely to improve outcome in patients with advanced non-small-cell lung cancer (NSCLC). Excision repair cross-complementation group 1 (ERCC1) is a promising biomarker; however, current evidence is inadequate. Impact of ERCC1 status was evaluated among patients participating in a large randomized chemotherapy trial.
Original language | English |
---|---|
Journal | Annals of Oncology |
Volume | 21 |
Issue number | 9 |
Pages (from-to) | 1817-24 |
Number of pages | 8 |
ISSN | 0923-7534 |
DOIs | |
Publication status | Published - 1 Sep 2010 |